Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score a data driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from GH Research ( (GHRS) ) is now available.
On February 3, 2025, GH Research PLC announced that their Phase 2b clinical trial for GH001, aimed at treating treatment-resistant depression (TRD), successfully met its primary endpoint. The trial demonstrated a significant placebo-adjusted reduction in depressive symptoms, with 57.5% of patients achieving remission by Day 8. The treatment was well-tolerated, with no serious adverse events reported, highlighting its potential to revolutionize intervention in psychiatry by offering a rapid, effective, and infrequent treatment option for TRD. The positive trial results mark a crucial milestone for GH Research, potentially positioning GH001 as a game-changer in depression treatment.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative therapies for depression, particularly treatment-resistant depression (TRD). The company’s lead product candidate, GH001, is an inhalable formulation of mebufotenin designed to provide rapid and profound antidepressant effects.
YTD Price Performance: 34.01%
Average Trading Volume: 78,959
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $551.5M
See more insights into GHRS stock on TipRanks’ Stock Analysis page.
